CN1308014C - Medicine for treating hepatitis B hepatitis C, hepatitis cirrhosis - Google Patents

Medicine for treating hepatitis B hepatitis C, hepatitis cirrhosis Download PDF

Info

Publication number
CN1308014C
CN1308014C CNB200410020842XA CN200410020842A CN1308014C CN 1308014 C CN1308014 C CN 1308014C CN B200410020842X A CNB200410020842X A CN B200410020842XA CN 200410020842 A CN200410020842 A CN 200410020842A CN 1308014 C CN1308014 C CN 1308014C
Authority
CN
China
Prior art keywords
hepatitis
medicine
treatment
liver
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200410020842XA
Other languages
Chinese (zh)
Other versions
CN1714834A (en
Inventor
张克
张亚军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB200410020842XA priority Critical patent/CN1308014C/en
Publication of CN1714834A publication Critical patent/CN1714834A/en
Application granted granted Critical
Publication of CN1308014C publication Critical patent/CN1308014C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a medicine for treating hepatitis B, C, hepatitis and hepatic cirrhosis, which belongs to traditional Chinese medicine. In order to solve problems, the present invention provides the medicine which has no side effect and has good treatment effects on the chronic hepatitis B, C, the hepatitis and the hepatic cirrhosis. The medicine is prepared by using roots of rubus crategefolius bge or using the roots of rubus crategefolius bge as a main material to be matched with conventional traditional Chinese medicine for treating the chronic hepatitis B, C, the hepatitis and the hepatic cirrhosis.

Description

A kind of medicine for the treatment of hepatitis B, hepatitis C, hepatitis cirrhosis
Technical field:
The present invention belongs to Chinese medicine.
Background technology:
Treatment chronic hepatitis B, hepatitis C, hepatitis cirrhosis still do not have specific drug at present.Now normal for the interferon that uses has certain curative effect to chronic hepatitis B, hepatitis C, hepatitis cirrhosis, for example: its stable response rate of treatment hepatitis C is only 15%-20% (interferon therapy hepatitis C effectiveness study: 56 pages of the 1st phases are rolled up in conjunction with hepatopathy magazine: 2002-12 in Chinese and Western); But side effect is big, relapse rate is high, cost an arm and a leg, and is not suitable for China's Medical Consumption level.
Summary of the invention:
The present invention is exactly at the problems referred to above, provides a kind of and has no side effect, and curative effect is treated the medicine of chronic hepatitis B, hepatitis C, hepatitis cirrhosis preferably.
The present invention mainly adopts following technical scheme: the present invention adopts TUOPANGEN or is that the main Chinese medicine that is equipped with conventional therapy chronic hepatitis B, hepatitis C, hepatitis cirrhosis is made with the TUOPANGEN.
TUOPANGEN is a natural plants, is the Rosaceae rubus, and hawthornleaf raspberry herb is used as medicine with root, the formal name used at school TUOPANGEN; The plant another name is the Fructus Rubi Radix Rubi crataegifolii.
Beneficial effect of the present invention:
1, without any side effects, this medicine is taken in natural plants, facts have proved without any side effects;
2, better curative effect is arranged, can obviously improve clinical symptoms in medication 3-7 days, effective percentage about 90% makes the HCV-RNA negative conversion rate up to about 60%; The individual month B ultrasonic finding of the 3-6 that takes medicine can be improved hepatic vein, portal vein, splenic vein measured value; And make that finding takes a turn for the better to some extent under the liver parenchyma mirror.
The specific embodiment:
Of the present invention producing: TUOPANGEN decocting in water or TUOPANGEN section back is pulverized or all can with industrial pharmaceutical equipment extraction.
The present invention also can be made into syrup, electuary, tablet, capsule, the watered pill, close ball, injection etc., and the method for making of these preparations is existing routine techniques.
Embodiment 1:
Getting TUOPANGEN 2-4 gram is a unit dose, and every day 2-3 time, three months is a course of treatment.
Embodiment 2:
TUOPANGEN 50-150 gram, Radix Salviae Miltiorrhizae 15-30 gram, Radix Bupleuri 5-15 gram, the Radix Paeoniae Alba 15 grams, Radix Glycyrrhizae 5 grams.
Embodiment 3:
TUOPANGEN 15-50 gram, Radix Panacis Quinquefolii 5-15 gram, Hedyotidis Diffusae 15-25 gram, Rhizoma Osmundae 10-20 gram.
Embodiment 4:
TUOPANGEN 3-100 gram, Radix Isatidis 15-30 gram.
The hardened clinical summary of this medicine treatment chronic hepatitis B regulating liver-QI
Since 96 years, the author adopts has the soothing liver and strengthening spleen removing dampness, this medicine treatment chronic hepatitis B of heat-clearing and toxic substances removing centralizing function, and hepatitis cirrhosis, clinical treatment 104 routine chronic hepatitis Bs and hepatitis patient with liver cirrhosis have been obtained obvious curative effects, are reported as follows:
1. materials and methods
1.1 case is selected: according to " viral hepatitis is prevented and treated scheme " the ordered diagnosis and the typing standard of in May, 95 Beijing the 5th whole nation infectious disease parasitic disease academic conference discussion revision, selected chronic hepatitis B and hepatitis patient with liver cirrhosis 164 examples 96 years in Mays, 2003: treatment group patient 104 examples, chronic hepatitis (comprise light in heavy) 54 examples (male 34 examples wherein, woman's 20 examples), in age 18-78 year, the mean age is (39 ± 7.9); Hepatitis cirrhosis patient 50 examples (male 35 examples, women 15 examples), age 30-74 year, the mean age is (45+12) year, is due to hepatitis B virus infects.Matched group 60 examples, chronic hepatitis B 31 examples (male 24 examples, women 7 examples) wherein, age 18-60 year, mean age is (32.7 ± 7.3), hepatitis cirrhosis 29 examples (male 23 examples, women 6 examples), age 29-74 year, mean age is (44 ± 10), two groups of patient ages, the sex and the state of an illness are similar, and comparability (P>0.05) is arranged.
1.2 Therapeutic Method: the treatment group is taken this medicine (capsule), and 8/time, 3 times/day, 3 months is a course of treatment.Matched group is taken liver-protecting tablet, and 5 slices/time, 3 times/day, the course of treatment is the same.Two groups of Primary Cares are identical.
1.3 observation item: ALT.AST.TBIL.DBIL.TP.ALB.TBA.GGT.ALP was checked in every month in before the treatment and treatment back, and used ultrasound diagnosis: portal vein. the splenic vein. and spleen thickness, finish (3 months) course of treatment, looks into five indexes of hepatitis b.The variation of itemized record patient symptom and sign simultaneously.
1.4 efficacy determination: produce effects: clinical symptoms (abdominal distention, pain in the hepatic region) disappears, and liver function is normal.Effectively: clinical symptoms takes a turn for the better, and liver function takes a turn for the better before the treatment.Invalid: the equal no change of clinical symptoms and liver function.
2. result
2.1 liver function recovery situation comparison before and after table 1 treatment (x ± s)
n ALT TBIL ALB
Before the treatment After the treatment Before the treatment After the treatment Before the treatment After the treatment
Treatment group (54) chronic hepatitis matched group (31) treatment group (50) liver cirrhosis matched group (29) 397.4±193.7 402.5±229.5 224.1±182.4 216.7±169.6 49.9±38.9 52.2±39.7 62.4±47.5 59.3±38.6 91.3±68.1 89.7±53.6 61.6±48.7 58.2±20.9 18.4±5.5 2 20.4±8.5 17.7±11.8 1 21.1±11.6 31.8±2.90 31.4±2.5 25.9±3.5 24.1±3.3 35.4±2.7 33.4±2.2 27.6±2.7 25.1±3.0
Annotate: with comparison P after the liver cirrhosis treatment of control group 1<0.05 with the chronic hepatitis treatment of control group after P relatively 2<0.01
2.2 the two groups of patient's liver B ultrasonic ultrasonograms in treatment back, the variation of spleen thickness and Portal system vessel diameter (seeing Table 2. tables 3)
Adopt Japanese Feitian black and white type B ultrasonic diagnostic apparatus, frequency probe is 3.5,50mHz.All cases are checked by same staff.Patient is empty stomach 12h before checking, under the eupnea state, does many internal organs of multiple sections ultrasonography such as liver and gall spleen pancreas kidney and writes down relevant data.
The detection of spleen thickness is as the criterion with hilus lienis place to the maximum normal distance of spleen outer rim tangent line.The measurement of the portal vein and the splenic vein, the maximum inner diameter with V of hepatic portal place and the spleen V of hilus lienis place is a standard respectively.
The B ultrasonic ultrasonogram of liver is mainly observed the left and right sides Ye Tiji size of liver, form, and the surface, liver parenchyma luminous point, many indexs such as vascular lake are with comprehensive judgement, by 4 grades of degree that are divided into liver damage.Standard is as follows:
1. roughly normal: above-mentioned every index is all no abnormal, or only have the liver parenchyma luminous point tiny → slightly thick.
2. mile abnormality: Ye Tiji size in the liver left and right sides is normal, the form polishing, and the peplos surface is owed smooth or is thickened, and the liver parenchyma luminous point is slightly thick → brighter → slightly bright, intensive, vascular lake is clear.
3. moderate is unusual: right lobe of liver lobus sinister volume increases or dwindles or normal substantially, and the peplos form: the peplos surface owes smooth, thickens or corrugated; In the liver luminous point slightly bright → coarse obviously intensive, companion or do not accompany the luminous point inequality, vascular lake is still clear or owe clearly.
4. severe is unusual: liver left and right sides leaf volume-diminished or increase, peplos form corrugated → zigzag → nodositas.In the liver luminous point thick → little lumps, distribute and owe all or uneven, vascular lake is unintelligible or owe clear.
The sonographic variation of patient's liver B ultrasonic before and after table 2 treatment
n Before treating (n) Treat back (n) Take a turn for the better
Roughly normal Gently In Heavy Normally Gently In Heavy n%
Treatment group (54) chronic hepatitis matched group (31) treatment group (50) liver cirrhosis matched group (29) 4 4 0 0 19 10 4 2 28 15 28 15 3 2 18 12 15 8 0 0 26 14 21 9 12 8 18 12 1 1 11 8 36/54 66.67 16/31 51.61 34/50 68.00 14/29 48.28
Compare P<0.05 with the primary disease matched group respectively
Table 2 shows treatment back chronic hepatitis, before liver cirrhosis is better than treatment respectively.
The variation of patient's portal vein blood vessel and spleen thickness before and after table 3 treatment (x ± s.mm)
n Inner diameter of portal vein Dsv Spleen thickness
Before the treatment After the treatment Before the treatment After the treatment Before the treatment After the treatment
Treatment group (54 chronic hepatitis matched group (31) treatment group (50) liver cirrhosis matched groups (29) 13.4±1.8 13.6±2.1 15.9±2.3 15.4±2.1 12.1±1.5 13.1±1.6 13.9±1.7 14.8±1.9 7.1±1.3 6.8±1.4 8.9±1.3 9.2±1.5 6.9±1.2 6.7±1.4 7.8±1.3 8.2±1.4 35.6±6.3 34.9±5.7 49.7±8.1 50.5±8.8 34.1±7.4 34.8±6.1 47.6±7.7 48.8±8.1
With comparison P<0.05 after the liver cirrhosis treatment of control group
2.3 comprehensive therapeutic effect [n (%)] before and after table 4 treatment
n Produce effects Effectively Invalid Total effective rate
Treatment group (54) chronic hepatitis matched group (31) treatment group (50) liver cirrhosis matched group (29) 28(51.85) 6(19.35) 24(48) 5(17.24) 22(40.74) 10(32.26) 14(28) 9(31.03) 4(7.41) 15(48.39) 12(24) 15(51.72) 92.59 51.61 76 48.27
Before table 4 shows that treatment back comprehensive therapeutic effect obviously is better than treatment
2.4 the observation of safety indexes before and after the treatment
This medicine is just conventional to patient's hematuria, electrocardiogram, and the kidney merit there is no untoward reaction.
2.5 hepatitis cirrhosis case
The Wang, woman, 43 years old, address: Beijing space flight bridge nuclear Second Academy
Main suit: suffer from chronic third hepatitis, spray interferon and take medicine and had a surplus the commentaries on classics of always not getting better in 2 years.Be in hospital at the beginning of 2002 1 month, late March ALT is in hospital again up to 170, and leave hospital again May Day later, and ascites hospitalization again on the 17th was left hospital, is in and takes medicine on the 26th.Be in hospital for the first time and once failed glucuronolatone, cause the blood glucose height, beat the interferon leukopenia, so the defeated glucuronolatone of being in hospital for the third time, defeated potenlin enters institute and has a blood test sugar normally, and other values HCV-RNA is 8.23 * 10 6 power copy/ml, TOTAL BILE ACID TBA 103.5, total protein 58, albumin 33, ALT 49, AST 33 (looking into before leaving hospital), B ultrasonic shows hepatitis C cirrhosis patients in decompensation, portal hypertension, ascites, splenomegaly, gallbladder multiple nodules, because the state of an illness is repeatedly, and is burning with anxiety, special searching Chinese traditional treatment.
Four diagnostic methods finding: patient's complexion is dark, and fatigue is weak, is difficult to walking, and often flu is assisted rib pain, and that presses aches very, right rib can be by the liver that reaches enlargement, and harder, abdominal distention is big, and the visible blue veins of stomach wall exposes the red tongue thick and greasy fur, the palm flushing, indigestion and loss of appetite, loose stool, oliguria and red, stringy pulse L)R.
Chinese medical discrimination: the healthy energy interior-deficiency, experience evil poison with the passing of time, heresy poisons wet, lingering damp-heat, disgruntled checking hyperfunction of the liver of while, stagnation of liver-QI with deficiency of the spleen, pathogen usually intruding into collateral in protracted disease, QI and blood is become silted up and is hindered, and forms QI and blood water with disease, and liver spleen kidney is all empty, very is refractory.
Diagnosis: the traditional Chinese medical science: tympanites; Doctor trained in Western medicine: hepatitis cirrhosis, chronic hepatitis C
The rule of treatment: soothing liver and strengthening spleen, the removing dampness detoxifcation is held concurrently to set upright.
Prescription: 8/time of this medicines 3 times/day, this medicine No. 2 2/time 3 times/day
Doctor's advice: as it is fair to urinate, and can refuse to obey diuretic, as it is bad to urinate, and can low dose ofly be interrupted the clothes diuretic, diet is eaten various melon with diuresis more, and white turnip is with pleasant, and balanced diet is good usually.
After on February 18th, 2003, the patient took medicine two months, fatigue, pain in the hepatic region takes a turn for the better, and can walk followingly, and diet is good, and abdominal distention disappears substantially, looks into AFP and reduces to 200.9mg/ml by 676.8, and HCV-RNA is reduced to 3.885 * 10 5 powers by 6.632 * 10 6 powers.
On July 14th, 2003, the state of an illness is clearly better over 5 months, and weight increase can normally be managed household affairs, and odd job is cooked etc.5 month do not go to hospital, the present go hospital check because of influenced by SARS February 18 to July 14, and main index is as follows as a result:
Because of some fatigue recently, outside ALT raise, all the other indexs all took a turn for the better, and with comparison on February 14, ALT reduces to 210 by 316, and TBA reduces to 22.80 by 44.90, and HCV-RNA is reduced to 1.945 * 10 4 powers by 3.885 * 10 5 powers.Advise and continue the treatment of this medicine of clothes.
On October 20th, 2003, patient did not catch a cold over 10 months, and health takes a turn for the better, and does not see other discomfort, ascites do not occur, and it is normal to urinate, and diet two is just all normal.October 17 chemical examination result shows: ALT 68, ALP195, and TBA 27.2,3 powers of HCV-RNA 7.675 * 10, AFP 141, and GGT 61, advise the patient to continue to take the treatment of this medicine, and No. 2, this medicine decrement is taken.
Discuss:
Chronic hepatitis and hepatitis cirrhosis are that the two is that the cause effect relation event merges discussion, and necrosis and inflammatory stimulus appear in hepatocyte repeatedly, pathologic connective tissue paraplasm in the liver, and reconstruction of lobules of liver structure or lobule formation then develop into liver cirrhosis.
This medicine is with its unique medical material and drug effect, the author uses this medicine treatment chronic hepatitis B 54 examples, hepatitis cirrhosis 50 examples, total effective rate is respectively 92.59% and 76% and matched group is respectively 51.61% and 48.27%, shows this medical instrument clinical symptoms that has clear improvement, and can improve patient's liver function effectively, anti-hepatic fibrosis, stablize the state of an illness, ALT.TBIL is comparatively fast descended, effect is obvious aspect the raising serum albumin.The author thinks that ALT mainly is present in the hepatocyte, and the breakage of liver plasma membrane is the main cause that ALT raises, and this medicine obviously transaminase lowering illustrates that it has the protection hepatocyte, repairs the effect of liver plasma membrane damage.
From the B ultrasonic result as can be seen, this medicine can more obviously improve the thickness of portal vein and Dsv and spleen, may improve the microcirculation of liver with the activating blood circulation to dissipate blood stasis removing dampness, reduces the generation and the deposition of extracellular matrix, promotes that collagen degradation is relevant.
This medicine treatment chronic hepatitis C 60 examples are summed up
1.1996 chronic hepatitis C 80 examples of year treatment in October in year October to 2003, clinical diagnosis all meets the diagnostic criteria that in JIUYUE, 2000 China medical association's infectious disease and the academic branch of parasitic disease hepatopathy credit meeting are revised, at random it is divided into treatment group (A group) 60 examples, wherein male 32 examples, woman's 28 examples, its mean age is 32 years old, and average course of disease is 11 years.Matched group (B group) 22 examples, wherein male 12 examples, women 10 examples, the mean age is 30 years old, average course of disease is 10.5.Two groups of patients are in sex, and at the age, aspects such as the course of disease have comparability (P>0.05).
2. Therapeutic Method:
The A group adopts this medicine, each 8,3 times/day.
The B group adopts homemade interferon-ALPHA 2a (FUKANGTAI) 3,000,000 units, intramuscular injection, 1 time/day.Treatment time is 6 months.
3. result:
3.1 changes of liver function comparison before and after two groups of treatments of table 1A.B (x ± s)
ALT(u/l) Normalization rate (%)
A group (n=60) B group (n=22) After treating before the preceding treatment of the treatment back treatment 328±194.21 33.47±12.62 176.52±87.72 36.97±22.87 85.00(51/60) 54.54(12/22)
The A group compares P<0.05 with the B group
3.2 (6 months) HCV-RNA and anti-HCV change relatively before and after the table 2 liang group patient treatment
Anti-HCV number positive Negative conversion rate The HCV-RNA number positive Negative conversion rate
A organizes (n=60) After treating before the treatment 60 58 3.33(2/60) 1 60 23 61.66(37/60) 2
B organizes (n=22) After treating before the treatment 22 22 0(22/22) 22 12 45.45(10/22)
P 1>0.05 P 2<0.05
3.3A the comparison of group group leader B efficient
A organize this medicine each 83 times/day 18 months
6 months+1miu of B group interferon 3miu tiw tiw 12 months
18 months effective percentage Permanently effective rate The ratio of the no HCV-RNA in treatment back Child-pgh scoring B changes the A level
A group B group 44.7% 26.7% 22.3% 9.9% 65.4% 27.6% 16% 4%
3.4 the case of this medicine treatment hepatitis C
Therapy for hepatitis C, foreign study think that HCV-RNA can be used as lasting effectively unique independent parameter (Chinese and Western is in conjunction with the 56th page of hepatopathy magazine 2002-12-1 phase of volume), and this medicine is turned out cloudy respond well to chronic hepatitis c HCV-RNA.
Case 1: Dong, man, 67 years old, the Jilin complete set of equipments veteran cadre of office
2003-5-14 day examines, and the main suit finds ALT and raises when having a fever before 2 years, the anti-HCV positive, HCV-RNA is 5.4 * 10 4 power copies/ml, is diagnosed as chronic hepatitis C in the Jilin Center Hospital, and patient's mental status still can, tired weak, the both hands liver palm is obvious.Took this medicine three months, each 8,3 times/day.2003-8-19 day examines, and patient's mental status is good, and fatigue alleviates, and liver palm is not obvious, checks that in this locality HCV-RNA is 0 copies/ml.
Case 2: revive certain, man, 18 years old, 2001-12-12 day examines, and lives Xinxiang, Henan, due to illness suspends schooling 1 year, disease is seen tired weak, the hepatalgia discomfort, and yellowish urine is red, ALT is 120u/l when examining, the anti-HCV positive, and HCV-RNA is 9.28 * 10 5 power copies/ml, B ultrasonic: thick 4.3 centimetres of spleen, viral typing Ib type had the blood transfusion history before 10 years, in Shanghai Infectious Disease Hospital, Henan Affiliated Hospital of Xinxiang College of Medical Science is diagnosed as chronic hepatitis C Ib type respectively.Because of considering that interferon is bigger to Ib type hepatitis C unsatisfactory curative effect and side effect, passing Jie through the patient comes me to treat, take each 8 of this medicine, 3 times/day, doing well,improving is rapid after 1 week of taking medicine, the patient was taking medicine 3 months respectively, 5 months, 7 months, carried out 4 HCV-RNA and detect in 10 months, take this medicine after 10 months HCV-RNA be 0 copies/ml, ALT is normal.
Case 3: the side certain, the woman, live in sea market (people from Shenyang City), because of acute nephritis is in hospital, hepatalgia, chance on the ALT height, TBIL is 23mmol/ml, the anti-HCV positive, hepatalgia enlargement tenderness is obvious, be diagnosed as chronic hepatitis C, examine, take this medicine and go back to Shanghai after 20 days on January 7th, 2003, looking into HCV-RNA in Shanghai City infectious hospital is 2.27 * 10 3 power copies/ml, take this medicine and look into HCV-RNA after 3 months again and transfer feminine gender to, ALT reduces to 50u/l by 120u/l, and hepatalgia is clearly better.(drug withdrawal on June 9) checked again once 2003-10-10 day to take this medicine 6 totally months, HCV-RNA or feminine gender.It is big slightly that JIUYUE was looked into the B ultrasonic leftlobe of liver on 17th, but the tenderness disappearance, this medicine of clothes that continues is consolidated a course of treatment.
Discuss:
This medicine is fit to chronic hepatitis (non-acute hepatitis first-selection), and it is longer to be suitable for the course of disease, and healthy energy is empty, and pathogen is reluctant to leave, the touching person of not healing.Its clinical manifestation is pain in the hepatic region or discomfort, the yellowish complexion lack of appetite, and fatigue and weak, abdominal distention, it is uncomfortable to defecate etc.Yin Ben group hepatitis C case was mostly caught an illness malicious about 10 years, had this clinical manifestation just to be found in varying degrees, so we are used for chronic hepatitis C with this medicine and above-mentioned clinical manifestation is disappeared very fast in recent years.
Interferon is mainly used in hepatitis C, the mechanism of action is the antiviral effect in the direct inducing cell, suppress HCV and duplicate, but very difficult effect of removing virus and interferon is subjected to multiple factor: as the age, the course of disease, ALT level and virus replication level, the HCV gene type, the influence of producer's technological level and ethnic group gene etc. is big because of its side effect again, the shortcoming that costs an arm and a leg etc. is used for compatriots and is difficult to obtain satisfied effect.So we compare this medicine and interferon, it is high inexpensive to be intended to find out a kind of effect, is suitable for compatriots' Chinese medicine.
As can be seen from Table 1, this medicine of A group clothes, B organizes injection of interferon, and the time is 6 months, and ALT normalization rate A group is 85%, and the B group is 54.54%, P value<0.05, thus illustrate that this medicine is better than interferon to the restitution of liver function.
As can be seen from Table 2, the situation of turning out cloudy of HCV-RNA, at present abroad HCV-RNA as the effective unique standard for the treatment of hepatitis c, negative conversion rate A group 61.66%, B group 45.45%, Δ P<0.05, illustrate HCV-RNA turn out cloudy aspect half a year (6 months) afterwards this medicine obviously be better than interferon.
Over 8 years, we have carried out tracing observation to 50 routine patients, and in the time of 18 months after the drug withdrawal, from symptom, the A group that sign, liver function several respects reach clinical cure accounts for 44.7% in medication, and 5-8 still has 22.3% conditions of patients stable.And 20 examples are used among the patient of interferon 26.7% stable disease were arranged in 18 months.Long-acting rate and the comparison of this medicine account for 9.9% the same period.The ratio A group of comparing treatment back serum-free virus the same period is 65.4%, and the B group is 27.6%.Wherein A group hepatitis C liver cirrhosis accounts for 12% by the child-pugh scoring by B level commentaries on classics A level, and B group (interferon) only accounts for 2%, and late result of this this medicine of explanation Chinese medicine is better than interferon.This may be the restriction that the Chinese medicine treatment must aim at the pathogenesis of disease is not subjected to course of disease length, has well transferred the immunoloregulation function of self, and the improvement of hepatic tissue is had better effect.

Claims (2)

1. TUOPANGEN is used for the treatment of purposes in the medicine of hepatitis C, hepatitis cirrhosis in preparation.
2. TUOPANGEN is used for the treatment of purposes in the medicine of hepatitis B in preparation, it is characterized in that only adopting TUOPANGEN as active component.
CNB200410020842XA 2004-06-28 2004-06-28 Medicine for treating hepatitis B hepatitis C, hepatitis cirrhosis Expired - Fee Related CN1308014C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB200410020842XA CN1308014C (en) 2004-06-28 2004-06-28 Medicine for treating hepatitis B hepatitis C, hepatitis cirrhosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB200410020842XA CN1308014C (en) 2004-06-28 2004-06-28 Medicine for treating hepatitis B hepatitis C, hepatitis cirrhosis

Publications (2)

Publication Number Publication Date
CN1714834A CN1714834A (en) 2006-01-04
CN1308014C true CN1308014C (en) 2007-04-04

Family

ID=35821195

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200410020842XA Expired - Fee Related CN1308014C (en) 2004-06-28 2004-06-28 Medicine for treating hepatitis B hepatitis C, hepatitis cirrhosis

Country Status (1)

Country Link
CN (1) CN1308014C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105477170A (en) * 2016-01-03 2016-04-13 刘志学 Medicine for treating liver diseases
CN105832855A (en) * 2016-05-28 2016-08-10 上饶市莎江高科生物有限公司 Traditional Chinese medicine oral liquid for treating hepatitis B and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159924A (en) * 1996-03-14 1997-09-24 张永辉 Liver and spleen health capsule
CN1228984A (en) * 1998-12-25 1999-09-22 青海省老年医学研究所 Medicine for anti-anoxia and treating chronic hepatitis
CN1244405A (en) * 1998-08-11 2000-02-16 张贤贵 Medicine for hepatitis B and its preparation
CN1403021A (en) * 2001-09-05 2003-03-19 韩完锡 Health food composition for liver

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159924A (en) * 1996-03-14 1997-09-24 张永辉 Liver and spleen health capsule
CN1244405A (en) * 1998-08-11 2000-02-16 张贤贵 Medicine for hepatitis B and its preparation
CN1228984A (en) * 1998-12-25 1999-09-22 青海省老年医学研究所 Medicine for anti-anoxia and treating chronic hepatitis
CN1403021A (en) * 2001-09-05 2003-03-19 韩完锡 Health food composition for liver

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
托盘根乙醇提取物的抗癌作用研究 杜钢军,实用肿瘤杂志,第2卷第17期 2002 *

Also Published As

Publication number Publication date
CN1714834A (en) 2006-01-04

Similar Documents

Publication Publication Date Title
CN1683001A (en) Chinese medicine for treating gout
CN103417846B (en) Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof
CN102462834A (en) Medicinal composition for controlling blood sugar of diabetic
CN1628768A (en) Medicine for treating gout affection and its symptoms
CN1159050C (en) Compound traditional Chinese medicine preparation for treating type 2 diabetes
CN1308014C (en) Medicine for treating hepatitis B hepatitis C, hepatitis cirrhosis
CN103877334A (en) Chinese medicinal liquor for treating rheumatoid arthritis and preparation method thereof
CN103961420A (en) Chinese medicinal composition for treating acute pancreatitis and application thereof
CN1840160A (en) Powder for resisting hyperosteogeny
CN105998558B (en) A kind of Chinese medicine composition and preparation method thereof for treating primary biliary cirrhosis
CN103751298B (en) A kind of Chinese medicinal enema for the treatment of chronic non-specific ulcerative colitis
CN102727605B (en) Oral liquid for treating vital myocarditis
CN103446410B (en) Traditional Chinese medicine preparation for treating viral myocarditis
CN1299762C (en) Chinese medicinal preparation for treating atrophic arthritis
CN106266307B (en) Ant bear gall pill and its preparation method and application
CN1291737C (en) Chinese medicine composition for treating icterus hepatitis
CN1212132C (en) Chinese medicine for treating rheumatic diseases and its prepn
CN106491974B (en) Traditional Chinese medicine composition and traditional Chinese medicine decoction for treating enteroparalysis
CN101045116A (en) Traditional Chinese medicine for treating cholecystitis
CN105106773B (en) A kind of Chinese medicine composition for treating gout
CN1269494C (en) Medicine for treating numbness and preparing method thereof
CN1114421C (en) Chinese medicine for treating diabetes
CN109758505A (en) A kind of Chinese medicine composition and its preparation method and application for treating urarthritis
CN1706443A (en) Liver fibrosis treating prepn and its process
CN102000297B (en) Traditional Chinese medical composition for treating coronary heart disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070404

Termination date: 20120628